Monte Rosa Therapeutics, Inc. GLUE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s stock-based comp?
- Monte Rosa Therapeutics, Inc. (GLUE) reported stock-based comp of $5.95M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s stock-based comp increased by 12.3% year-over-year, from $5.3M to $5.95M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s stock-based comp has grown at a 38.0% compound annual growth rate (CAGR), from $5.2M to $18.87M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.